Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.

Julie KanterMark C WaltersLakshmanan KrishnamurtiMarkus Y MaparaJanet L KwiatkowskiStacey Rifkin-ZenenbergBanu AygunKimberly A KasowFrancis J PiercieyMelissa BonnerAlex MillerXinyan ZhangJessie LynchDennis KimJean-Antoine RibeilMohammed AsmalSunita GoyalAlexis A ThompsonJohn F Tisdale

Published in: The New England journal of medicine (2021)

in most red cells, leading to reduced hemolysis and complete resolution of severe vaso-occlusive events. (Funded by Bluebird Bio; HGB-206 ClinicalTrials.gov number, NCT02140554.).

Keyphrases

sickle cell disease
induced apoptosis
cell cycle arrest
rheumatoid arthritis
early onset
single molecule
oxidative stress
pi k akt